Evaluation of COMT Gene rs4680 Polymorphism as a Risk Factor for Endometrial Cancer.

Catechol-O-methyletransferase (COMT) enzyme is involved in the inactivation of catecholamine and catechol estrogens. Catechol estrogens have carcinogenic potential and DNA damaging ability. Several studies investigated COMT Val158Met polymorphism as risk factor for endometrial cancer but the results were inconclusive. Hence the objective of present study was to find out exact association between COMT gene Val158Met polymorphism and endometrial cancer by a meta-analysis. Pubmed, Google Scholar, Springer Link and Science Direct databases were searched for case-control articles which investigated COMT Val158Met polymorphism in endometrial cancer cases. All statistical analysis was performed using MetaAnalyst and Mix programs. The results of meta-analysis suggested that there were no association between COMT Val158Met polymorphism and endometrial cancer risk (allele contrast model-OR = 0.97, 95% CI = 0.86-1.10,  = 0.67; co-dominant model-OR = 0.91, 95% CI = 0.77-1.06,  = 0.23; homozygote model-OR = 1.01, 95% CI = 0.84-1.19,  = 0.29; dominant model-OR = 0.93, 95% CI = 0.77-1.11,  = 0.43; recessive model-OR = 1.02, 95% CI = 0.89-1.20,  = 0.62). Publication bias was absent. Subgroup analysis based on source of controls was also performed. In conclusion, results of present meta-analysis showed no association between COMT Val158Met polymorphism and susceptibility to endometrial cancer.